Primary pulmonary choriocarcinoma in a male that was successfully diagnosed and treated: A case report and review of the literature. Issue 52 (December 2016)

• Record Type: Journal Article
• Authors: Zhu, Ran; Jia, Congwei; Yan, Jie; Luo, Yufeng; Huo, Zhen
• Other Names: Liu. Yong section editor.
• Is Part Of: Medicine. Volume 95:Issue 52(2016)
• Publication Date: 2016-12
• Subjects: beta-human chorionic gonadotropin -- male -- primary pulmonary choriocarcinoma; Medicine -- Periodicals; Medicine -- Periodicals; Médecine -- Périodiques; Geneeskunde; Medicine; Periodicals; Periodicals; 610.5
• DOI: 10.1097/MD.0000000000005693
• Languages: English
• ISSNs: 0025-7974

Abstract

Abstract: Introduction: Primary pulmonary choriocarcinoma (PPC) is extremely rare, especially in males. It is characterized by a poor response to therapy and shortened survival times. Here, we report a successful diagnosis and modified treatment for PPC in a male and a review of the literature. Case presentation: This case report describes a 67-year-old male who was discovered to have a left pulmonary mass. The patient underwent a pulmonary lobectomy. Pathological examination showed a poorly biphasic differential tumor. Immunostaining displayed that beta-human chorionic gonadotropin (β-HCG), CD10, and GATA3 were positive, and the increase of postoperative serum β-HCG secretion was also confirmed. Systemic and genital screening was performed, but other abnormal findings were not observed. The diagnosis of PPC was confirmed. Then, the patient received 4 cycles of modified chemotherapy according the condition of his body. The patient has been alive for >13 months without recurrence, and the level of serum β-HCG has already decreased to normal. In addition to reporting this case, we have also summarized the similar previously published cases. Conclusions: Currently, there is no standard treatment for PPC. A rapid and correct diagnosis is necessary. Surgery and modified chemotherapy, based on the physical condition of the patient, may currently be the best therapy for PPC.